Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Phase II study of trabectedin in pretreated patients with advanced colorectal cancer.
Paz-Ares L, Rivera-Herreros F, Díaz-Rubio E, García M, Casado E, Cubedo R, Gravalos C, Alfaro V, Gómez J, Izquierdo MA, Tabernero J. Paz-Ares L, et al. Among authors: alfaro v. Clin Colorectal Cancer. 2007 May;6(7):522-8. doi: 10.3816/CCC.2007.n.018. Clin Colorectal Cancer. 2007. PMID: 17553201 Clinical Trial.
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum.
Massuti B, Cobo M, Camps C, Dómine M, Provencio M, Alberola V, Viñolas N, Rosell R, Tarón M, Gutiérrez-Calderón V, Lardelli P, Alfaro V, Nieto A, Isla D. Massuti B, et al. Among authors: alfaro v. Lung Cancer. 2012 Jun;76(3):354-61. doi: 10.1016/j.lungcan.2011.12.002. Epub 2011 Dec 23. Lung Cancer. 2012. PMID: 22197612 Clinical Trial.
Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J, Subbiah V, Besse B, Moreno V, López R, Sala MA, Peters S, Ponce S, Fernández C, Alfaro V, Gómez J, Kahatt C, Zeaiter A, Zaman K, Boni V, Arrondeau J, Martínez M, Delord JP, Awada A, Kristeleit R, Olmedo ME, Wannesson L, Valdivia J, Rubio MJ, Anton A, Sarantopoulos J, Chawla SP, Mosquera-Martinez J, D'Arcangelo M, Santoro A, Villalobos VM, Sands J, Paz-Ares L. Trigo J, et al. Among authors: alfaro v. Lancet Oncol. 2020 May;21(5):645-654. doi: 10.1016/S1470-2045(20)30068-1. Epub 2020 Mar 27. Lancet Oncol. 2020. PMID: 32224306 Clinical Trial.
Trabectedin has a low cardiac risk profile: a comprehensive cardiac safety analysis.
Lebedinsky C, Gómez J, Park YC, Nieto A, Soto-Matos A, Parekh T, Alfaro V, Roy E, Lardelli P, Kahatt C. Lebedinsky C, et al. Among authors: alfaro v. Cancer Chemother Pharmacol. 2011 Nov;68(5):1223-31. doi: 10.1007/s00280-011-1614-z. Epub 2011 Mar 18. Cancer Chemother Pharmacol. 2011. PMID: 21416137 Clinical Trial.
Phase I and pharmacokinetic study of trabectedin 3-hour infusion every three weeks in patients with advanced cancer and alteration of hepatic function.
Pardo B, Salazar R, Ciruelos E, Cortés-Funes H, García M, Majem M, Montes A, Cuadra C, Soto-Matos A, Lebedinsky C, Alfaro V, Paz-Ares L. Pardo B, et al. Among authors: alfaro v. Med Oncol. 2012 Sep;29(3):2240-50. doi: 10.1007/s12032-011-9979-8. Epub 2011 Jun 10. Med Oncol. 2012. PMID: 21660618 Clinical Trial.
First-in-man phase I trial of two schedules of the novel synthetic tetrahydroisoquinoline alkaloid PM00104 (Zalypsis) in patients with advanced solid tumours.
Yap TA, Cortes-Funes H, Shaw H, Rodriguez R, Olmos D, Lal R, Fong PC, Tan DS, Harris D, Capdevila J, Coronado C, Alfaro V, Soto-Matos A, Fernández-Teruel C, Siguero M, Tabernero JM, Paz-Ares L, de Bono JS, López-Martin JA. Yap TA, et al. Among authors: alfaro v. Br J Cancer. 2012 Apr 10;106(8):1379-85. doi: 10.1038/bjc.2012.99. Br J Cancer. 2012. PMID: 22491421 Free PMC article. Clinical Trial.
129 results